Incyte Reports 14% Revenue Growth in Q3 2026 Driven by Opzelura and Oncology Sales
Incyte Corporation (INCY) reported strong third-quarter results for 2026, with total revenue reaching $1.56 billion, a 14% increase year-over-year. Growth was fueled by significant gains in the company's core business excluding Jakafi, which grew 30%, and robust performance from Opzelura ($255 million) and its Hematology and Oncology segment ($235 million). Despite a massive 254% surge in R&D expenses due to a $1.23 billion one-time charge related to the Vega Therapeutics acquisition, Incyte raised its full-year net sales guidance to between $5.21 billion and $5.3 billion. The company is actively transitioning its revenue base toward newer growth brands while managing clinical execution risks in its Phase III pipeline.
Tickers: $INCY
Topics: acquisition biotechnology clinical efficacy guidance raise revenue growth